Phaseline

Targets › APP

APP (Amyloid-beta precursor protein): drug programs, companies and trials

18 programs from 15 companies in 38 trials: 16 Phase 2, 13 Phase 3, 6 Phase 1, 3 Phase 4; Neurology, Other; next expected readout Nov 2026.

Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis. (UniProt, P05067)

Open in Phaseline: the race on APP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
JYAMS PET Research & Development[18F]-APN-1607
Positron emission tomography (PET) imaging agent for detecting amyloid-beta pathology in A
APPPhase 3Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia; Alzheimer's DiseaseDec 2026
EisaiLecanemab (BAN2401)
Amyloid-beta A4 protein inhibitor
APPPhase 3Early Alzheimer's Disease; Preclinical Alzheimer's Disease; Alzheimer's Disease; Alzheimer's Disease(AD) …Dec 2026
Eli LillyDonanemab (LY3002813)
Amyloid-beta A4 protein disrupting agent
APPPhase 3Alzheimer's Disease; Alzheimer Disease; Cognitive Dysfunction; Autosomal Dominant Alzheimers DiseaseMay 2027
HTA[18F]Fluorbetazine injection
PET tracer for amyloid-beta plaque imaging
APPPhase 3Mild Cognitive Impairment (MCI)Dec 2027
RocheRO7269162
BACE1 inhibitor
APPPhase 2Alzheimer's DiseaseNov 2026
Columbia University18F-Florbetaben
Amyloid PET imaging tracer that binds to amyloid-beta deposits
APPPhase 2Alzheimer DiseaseDec 2026
Alnylam PharmaceuticalsALN-APP
siRNA targeting amyloid precursor protein (APP)
APPPhase 2Cerebral Amyloid Angiopathy; Early-Onset Alzheimer DiseaseAug 2027
Washington University School of MedicineGantenerumab
Amyloid-beta A4 protein binding agent
APPPhase 2Alzheimers DiseaseApr 2028
Washington University School of MedicineSolanezumab
Amyloid-beta A4 protein binding agent
APPPhase 2Alzheimers DiseaseApr 2028
University of Alabama at Birmingham[C-11]PiB
PET imaging agent that binds to amyloid-beta protein
APPPhase 2Alzheimer DiseaseOct 2028
Alnylam PharmaceuticalsMivelsiran
Antisense oligonucleotide targeting APP mRNA
APPPhase 2Down Syndrome-Associated Alzheimer's Disease (DS-AD)May 2030
Akiva Mintz18F-Florbetapir
Amyloid-beta PET imaging agent
APPPhase 2Alzheimer DiseaseJun 2030
Acumen Pharmaceuticalssabirnetug
anti-amyloid-beta protofibrils monoclonal antibody
APPPhase 2Alzheimer Disease–
Amyloid SolutionAS-S603
Small molecule targeting amyloid-beta and tau aggregates
APP, MAPTPhase 1HealthyDec 2026
Texas Tech University Health Sciences CenterCurcumin
Polyphenolic compound targeting amyloid-beta aggregation and tau pathology; crosses blood-
ABCB1, APP, MAPTPhase 1BioavailabilityDec 2026
NuravaxDUVAX
Vaccine targeting amyloid-beta and tau proteins
APP, MAPTPhase 1Alzheimer DiseaseApr 2027
RocheRO7126209
Anti-amyloid beta monoclonal antibody
APPPhase 1Alzheimers DiseaseJul 2027
National Institute of Mental Health (NIMH)18f-florbetaben
Amyloid-beta PET tracer
APPPhase 1Parkinson's DiseaseApr 2029

Conditions

Alzheimer Disease (13) Alzheimer's Disease (6) Alzheimers Disease (5) Bioavailability (1) Cognitive Dysfunction (1) Autosomal Dominant Alzheimers Disease (1) Early Alzheimer's Disease (1) Preclinical Alzheimer's Disease (1) Alzheimer's Disease(AD) (1) Alzheimer s Disease (1) Cerebral Amyloid Angiopathy (1) Early-Onset Alzheimer Disease (1)

Modalities

small molecule (9), antibody (3), mixed (3), other (2), protein or peptide (1)

Companies

Alnylam Pharmaceuticals (2) Washington University School of Medicine (2) Roche (2) Texas Tech University Health Sciences Center (1) Eli Lilly (1) Eisai (1) Acumen Pharmaceuticals (1) Columbia University (1) JYAMS PET Research & Development (1) Akiva Mintz (1) Amyloid Solution (1) HTA (1) University of Alabama at Birmingham (1) Nuravax (1) National Institute of Mental Health (NIMH) (1)

Related targets

MAPT (3) ABCB1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.